M4MM

Compass Pathways Advances Psilocybin Research in the UK

LOS ANGELES- Compass Pathways, a biotechnology company specializing in mental health innovations, has commenced the UK segment of its global Phase 3 clinical trial evaluating COMP360 psilocybin therapy for treatment-resistant depression (TRD). This initiative follows ...

Compass Pathways Advances Psilocybin Research in the UK

LOS ANGELES- Compass Pathways, a biotechnology company specializing in mental health innovations, has commenced the UK segment of its global Phase 3 clinical trial evaluating COMP360 psilocybin therapy for treatment-resistant depression (TRD). This initiative follows ...

Subscribe To Our Newsletter